rsv f subunit vaccine + aluminum hydroxide

The rsv f subunit vaccine + aluminum hydroxide is a **combination vaccine** consisting of a **recombinant RSV F protein subunit** (the fusion glycoprotein of respiratory syncytial virus) formulated with **aluminum hydroxide** as an adjuvant. The RSV F protein subunit acts as the immunogen, while the aluminum hydroxide enhances the immune response by serving as an adjuvant. Aluminum hydroxide promotes antigen uptake, enhances both humoral (antibody) and cellular immune responses, and facilitates antigen presentation by dendritic cells and macrophages. This vaccine is under clinical investigation as a prophylactic against **respiratory syncytial virus infection**. The active RSV F subunit protein is typically produced recombinantly, and the vaccine often targets prevention of RSV disease in various at-risk populations such as infants, older adults, and pregnant women. The recombinant protein is adsorbed onto aluminum hydroxide prior to administration, resulting in enhanced activation of CD4+ T cells and development of immunological memory. Developers have included biotechnology and pharmaceutical companies specializing in vaccine research, with aluminum hydroxide supplied as a standardized pharmaceutical adjuvant[1][3][5][8][9].